<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485418</url>
  </required_header>
  <id_info>
    <org_study_id>STU 042014-002</org_study_id>
    <nct_id>NCT02485418</nct_id>
  </id_info>
  <brief_title>Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients</brief_title>
  <acronym>Propofol2014</acronym>
  <official_title>Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propofol has been used in adult populations to treat migraines as an abortive agent.&#xD;
      Investigators plan to investigate its efficacy as an abortive agent in the pediatric&#xD;
      population when administered as a safe low-dose infusion. Goals of the study are to:&#xD;
&#xD;
        1. Evaluate efficacy of low-dose propofol infusion as an abortive agent in pediatric&#xD;
           migraine headaches&#xD;
&#xD;
        2. Evaluate effective and safe dosing limits in pediatric populations&#xD;
&#xD;
        3. Evaluate duration of effect reached from a low-dose propofol infusion as an abortive&#xD;
           agent&#xD;
&#xD;
      Endpoints for the study will be:&#xD;
&#xD;
        1. Number of enrolled patients&#xD;
&#xD;
        2. Safety endpoints reached, including: cardiopulmonary depression, excessive somnolence&#xD;
           Risks of the study are minimal due to the use of sub-anesthetic dosing of propofol under&#xD;
           the guidance and supervision of a board certified pediatric anesthesiologist with the&#xD;
           appropriate monitoring equipment and readily available emergency equipment.&#xD;
           Investigators hope to demonstrate more rapid improvement and decreased side-effect as&#xD;
           compared to standard care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Headache Pain Score</measure>
    <time_frame>Duration of propofol infusion (between 5 and 60 minutes)</time_frame>
    <description>Reduction in pain score on 0-10 Numeric Pain Rating Scale. Subjects assessed at 5 minute intervals for the duration of the infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>Assessments at 10 minute intervals from the start of infusion while on site, and at 24 and 48 hours after discharge, up to 72 hours.</time_frame>
    <description>For subjects who experience improvement in pain score or who report resolution from headache symptoms, duration of analgesia up to 48 hours after treatment,characterized by NPRS Pain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total propofol dose</measure>
    <time_frame>60 minutes</time_frame>
    <description>Total dose of propofol administered (mg/kg)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>Propofol infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be treated with an intravenous propofol infusion at the following escalating rate schedule:&#xD;
20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.</description>
    <arm_group_label>Propofol infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of migraine headache per ICHD - 3 (International&#xD;
             Classification of Headache Disorders)&#xD;
&#xD;
          -  The subjects will have a history of migraine headaches with a presentation consistent&#xD;
             with presentations of their headaches in the past with no indication for further&#xD;
             investigation for secondary causes of his/her headache&#xD;
&#xD;
          -  Documented pain score greater than or equal to 6 on a 0-10 Numeric Pain Rating Scale&#xD;
&#xD;
          -  Current migraine has a greater than 24 hours duration with a current pain score of 6&#xD;
             or greater on a 0-10 Numeric Pain Rating Scale&#xD;
&#xD;
          -  Subjects will be scheduled for DHE infusion therapy for treatment of migraines per&#xD;
             standard medical care&#xD;
&#xD;
          -  Patients age 7-18 years old&#xD;
&#xD;
          -  Gender: both male and female&#xD;
&#xD;
          -  Appropriate fasting interval as per ASA guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No long acting triptan therapy within 24 hours&#xD;
&#xD;
          -  No shorter acting triptan therapy within 6 hours&#xD;
&#xD;
          -  No ergot alkaloid derivatives within the last 24 hours&#xD;
&#xD;
          -  No opioid within 2 hours&#xD;
&#xD;
          -  No NSAID or acetaminophen within 1 hour of infusion&#xD;
&#xD;
          -  Use of sedative medications within 6 hours of infusion, including opioids,&#xD;
             benzodiazepines, barbiturates&#xD;
&#xD;
          -  Headache not consistent with subject's headache history needing further work-up&#xD;
&#xD;
          -  Headache duration less than 24 hours&#xD;
&#xD;
          -  Subjects in which an intravenous line could not be secured&#xD;
&#xD;
          -  Subjects with history of significant reflux or hiatal hernia&#xD;
&#xD;
          -  Subjects with history of significant cardio pulmonary disorders&#xD;
&#xD;
          -  Patient not fasting as per ASA guidelines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deryk Walsh, MD</last_name>
    <phone>214-456-6393</phone>
    <email>deryk.walsh@childrens.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Schutt</last_name>
    <phone>214-456-8981</phone>
    <email>jordan.schutt@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Health Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Schutt</last_name>
      <phone>214-456-8981</phone>
      <email>jordan.schutt@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Deryk Walsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Deryk Walsh</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

